secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2026-08-12T20:09:51+00:00
Accession:  0001437749-26-027313
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Q2: YARTEMLEA net rev $28.5M (+190% QoQ); adjusted EPS $0.02 vs -$0.24
-----------------------------------------------------------------------------

- YARTEMLEA net revenue $28.5M in Q2 2026 (gross $32.2M), up 190% from Q1 gross $11.1M; gross-to-net ~11.5%.
- GAAP net income $13.2M ($0.18/sh) vs $56.1M ($0.78) in Q1; non-GAAP adjusted net income $1.8M ($0.02) vs -$17.1M ($0.24).
- Cash and short-term investments $132.0M at June 30, 2026; Q2 operating cash flow $4.1M.
- In July, repurchased $30.5M principal of 2029 notes for $60.2M, cutting outstanding to $40.3M and conversion shares from ~11.4M to 6.5M.
- CHMP negative opinion on narsoplimab MAA for TA-TMA in June; re-examination requested. J-code effective July 1, NTAP effective Oct 1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000143774926027313/0001437749-26-027313-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000143774926027313/omer20260521_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-027313

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer